Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hajek, Roman
NCT01788020 / 2013-000506-37: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Completed	3	202	Europe	Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib	University of Ulm, Centre Hospitalier de Lens (Co-Sponsor)	Waldenström's Macroglobulinemia	11/18	04/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma	Completed	1/2	272	Europe, Canada, Japan, US, RoW	Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	07/24	11/24
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma	Completed	1/2	15	Europe, Canada, US, RoW	Modakafusp Alfa, TAK-573, Daratumumab	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	05/24	05/24
EMN-COVID, NCT04492371: COVID-19 Infection and Multiple Myeloma	Completed	N/A	1054	Europe, RoW		Stichting European Myeloma Network, Fondazione EMN Italy Onlus	Multiple Myeloma, Covid19, Corona Virus Infection	08/22	03/24